Connect with us

Health & Fitness

Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes

In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals. Reuters Health Information

Published

on

Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes

In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals. Reuters Health Information
Read More